keyword
MENU ▼
Read by QxMD icon Read
search

infliximab level

keyword
https://www.readbyqxmd.com/read/29474531/subtherapeutic-infliximab-trough-levels-and-complete-mucosal-healing-are-associated-with-sustained-clinical-remission-after-infliximab-cessation-in-paediatric-onset-crohn-s-disease-patients-treated-with-combined-immunosuppressive-therapy
#1
Ben Kang, So Yoon Choi, Young Ok Choi, Min-Ji Kim, Kyunga Kim, Ji-Hyuk Lee, Yon Ho Choe
Background and aims: We aimed to investigate the outcome in paediatric-onset Crohn's disease patients who had discontinued infliximab after maintaining clinical remission with combined immunosuppression, and to determine factors associated with clinical relapse. Methods: We conducted a retrospective observational study of 63 paediatric-onset Crohn's disease patients who had stopped scheduled infliximab during sustained corticosteroid-free clinical remission for at least 1 year with infliximab and azathioprine, and were followed up for at least 1 year thereafter...
February 21, 2018: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/29464314/activation-status-of-peripheral-blood-neutrophils-and-the-complement-system-in-adult-rheumatoid-arthritis-patients-undergoing-combined-therapy-with-infliximab-and-methotrexate
#2
Larissa F Marchi, Adriana B Paoliello-Paschoalato, Renê D R Oliveira, Ana Elisa C S Azzolini, Luciana M Kabeya, Eduardo A Donadi, Yara Maria Lucisano-Valim
We examined the functional activity of peripheral blood neutrophils and the complement system activation status in patients with rheumatoid arthritis (RA) undergoing infliximab/methotrexate combined therapy. We studied female RA patients under treatment with infliximab (3-5 mg/kg) and methotrexate (15-25 mg/week) who presented inactive (i-RA; n = 34, DAS-28 ≤ 2.6) or at least moderately active disease (a-RA; n = 29, DAS-28 > 3.2), and age-matched healthy women (n = 38). We measured the levels of reactive oxygen species (ROS) generation (chemiluminescence assay) and membrane expression of FcγRIIa/CD32, FcγRIIIb/CD16, CR1/CD35, and CR3/CD11b receptors (ELISA assay) in neutrophils...
February 20, 2018: Rheumatology International
https://www.readbyqxmd.com/read/29462398/full-interchangeability-in-regard-to-immunogenicity-between-the-infliximab-reference-biologic-and-biosimilars-ct-p13-and-sb2-in-inflammatory-bowel-disease
#3
Gionata Fiorino, M Begoña Ruiz-Argüello, Ainara Maguregui, Daniel Nagore, Carmen Correale, Simona Radice, Daniela Gilardi, Mariangela Allocca, Federica Furfaro, Antonio Martínez, Silvio Danese
Background: Infliximab (IFX) biosimilars CT-P13 and SB2 have comparable efficacy, safety, and immunogenicity to the originator Remicade (RMC). However, concerns about cross-switching patients between the 3 brands were raised in the absence of cross reactivity data between them. We aimed to determine whether antibodies to infliximab (ATI) in inflammatory bowel disease (IBD) patients cross-react with RMC, CT-P13, and SB2. Methods: Based on previous ATI status, samples from 34 patients participating in the BIOSIM01 study (13 RMC, 9 CT-P13, and 12 switchers) were selected...
February 15, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29458298/%C3%AE-amyloid-inhibits-hippocampal-ltp-through-tnfr-ikk-nf-%C3%AE%C2%BAb-pathway
#4
Manikandan Samidurai, Vijay S Ramasamy, Jihoon Jo
Objective The suppressive action of the acute application of oligomeric amyloid-β (Aβ) on hippocampal long-term potentiation (LTP) has been reported widely. Many mechanisms have been proposed for Aβ inhibited LTP induction. The inflammatory cytokine tumor necrosis factor-α (TNF-α) has also been reported to play a key role in this LTP inhibition through Aβ. However, the underlying molecular mechanisms are largely unknown. This study aimed to investigate the link between Aβ- and TNF-α-mediated hippocampal LTP inhibition...
February 20, 2018: Neurological Research
https://www.readbyqxmd.com/read/29446129/editorial-infliximab-trough-levels-and-histological-healing-in-ulcerative-colitis-a-step-towards-personalised-biologic-therapy
#5
EDITORIAL
T Lobaton, M De Vos
No abstract text is available yet for this article.
March 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29446128/editorial-restoring-therapeutic-infliximab-drug-levels-in-patients-with-loss-of-response-pharmacokinetics-and-anti-drug-antibodies-as-useful-guidance-tools
#6
EDITORIAL
S Ben-Horin
No abstract text is available yet for this article.
March 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29446098/safety-efficacy-and-pharmacokinetics-of-vedolizumab-in-patients-with-simultaneous-exposure-to-an-anti-tumour-necrosis-factor
#7
S Ben-Horin, B Ungar, U Kopylov, A Lahat, M Yavzori, E Fudim, O Picard, Y Peled, R Eliakim, E Del Tedesco, S Paul, X Roblin
BACKGROUND: Data on combination-biologic treatment in (IBD) are still scant. AIM: To explore outcomes of patients co-exposed to anti-TNF and vedolizumab. METHODS: Patients starting vedolizumab having measurable anti-TNF levels after recently stopping adalimumab/infliximab ('VDZ-aTNF' group), were compared with control vedolizumab patients in a retrospective 1:2 matched case-control study. RESULTS: Seventy-five patients were included (25 VDZ-aTNF, 50 VDZ)...
February 15, 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29445863/use-of-biological-disease-modifying-antirheumatic-drugs-in-rheumatoid-arthritis-in-austria-from-2008-to-2011-a-retrospective-analysis-of-72-of-the-population
#8
Tanja A Stamm, Berthold Reichardt, Jochen Zwerina, Valentin Ritschl, Valerie Nell-Duxneuner
BACKGROUND: Rheumatoid arthritis (RA) is the most prevalent chronic inflammatory joint disease. On a national level in Austria, there are currently no data available on how often and which biological disease modifying antirheumatic drugs (bDMARDs) are prescribed in patients with RA. The aim of the present study was to explore prescription patterns of bDMARDs in RA in Austria with a focus on drug survival. METHODS: A retrospective data analysis of bDMARD courses of individual patients with RA that were extracted from the databases of nine Austrian health insurance funds covering 6...
February 14, 2018: Wiener Klinische Wochenschrift
https://www.readbyqxmd.com/read/29439591/assessment-of-effectiveness-and-safety-of-biosimilar-infliximab-ct-p13-in-a-real-life-setting-for-treatment-of-patients-with-active-rheumatoid-arthritis-or-ankylosing-spondylitis
#9
Cătălin Codreanu, Klára Šírová, Katerina Jarošová, Anastas Batalov
OBJECTIVE: To assess the effectiveness and safety of infliximab biosimilar, CT-P13, administered in a real-life setting to adult patients with active rheumatoid arthritis (RA) or ankylosing spondylitis (AS). METHODS: This multicentre, non-interventional, observational study was conducted in Bulgaria, Czech Republic and Romania. A total of 151 patients with severe active RA (n = 81) or AS (n = 70) were enrolled and treated with CT-P13 for 24 weeks, according to current medical recommendations...
February 13, 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29434844/oxaliplatin-and-infliximab-synergize-to-induce-regression-of-colon-cancer
#10
Di Huang, Jun Xue, Shuguang Li, Dongdong Yang
There is currently a lack of therapeutic options for patients with advanced colon cancer. Although certain chemotherapies are able to suppress the progression slightly, the response rate is low, and side effects of treatment and tumor recurrence continue to present problems for clinicians. Tumor necrosis factor-α (TNF-α) has been identified to possess tumor-promoting properties. In the present study, the effect of anti-TNF-α treatment (infliximab) in combination with chemotherapy on colon cancer was investigated...
February 2018: Oncology Letters
https://www.readbyqxmd.com/read/29431302/the-new-test-for-monitoring-infliximab-therapy-from-laboratory-to-clinical-practice
#11
Elena De Santis, Alessandra Melegari, Chiara Bonaguri, Gilda Sandri, Maria Teresa Mascia, Federica Gaiani, Valentina Pecoraro, Gianluigi De Angelis, Tommaso Trenti
BACKGROUND: Biological agents for anti-tumor necrosis factor-α therapy have revolutionized treatments for autoimmune diseases; however, approximately 20% of rheumatology and 40% of gastroenterology patients do not respond to the therapy, or they show reduced drug efficacy because of anti-drug antibody (ADA) formation. OBJECTIVES: To evaluate laboratory tools for individual monitoring of infliximab therapy and the relationship between ADA and infliximab serum levels, ADA and clinical response, and ADA and autoantibodies...
February 2018: Israel Medical Association Journal: IMAJ
https://www.readbyqxmd.com/read/29430171/correlation-between-hla-haplotypes-and-the-development-of-antidrug-antibodies-in-a-cohort-of-patients-with-rheumatic-diseases
#12
Maurizio Benucci, Arianna Damiani, Francesca Li Gobbi, Francesca Bandinelli, Maria Infantino, Valentina Grossi, Mariangela Manfredi, Guillaume Noguier, Francesca Meacci
Introduction: The aim of this study was to investigate the correlation between human leukocyte antigen (HLA) haplotypes and the development of antidrug antibodies (ADAs) in a cohort of patients with rheumatic diseases. Patients and methods: We evaluated the presence of ADAs in 248 patients with inflammatory rheumatic diseases after 6 months of treatment with anti-TNF drugs: 26 patients were treated with infliximab (IFX; three with rheumatoid arthritis [RA], 13 with ankylosing spondylitis [AS], 10 with psoriatic arthritis [PsA]); 83 treated with adalimumab (ADA; 24 with RA, 36 with AS, 23 with PsA); 88 treated with etanercept (ETA; 35 with RA, 27 with AS, 26 with PsA); 32 treated with certolizumab (CERT; 25 with RA, two with AS, five with PsA); and 19 treated with golimumab (GOL; three with RA, seven with AS, nine with PsA)...
2018: Biologics: Targets & Therapy
https://www.readbyqxmd.com/read/29421215/sweeping-of-adsorbed-therapeutic-protein-on-prefillable-syringes-promotes-micron-aggregate-generation
#13
Takahiro Maruno, Hiroki Watanabe, Saki Yoneda, Takayuki Uchihashi, Satoru Adachi, Kunihito Arai, Taichi Sawaguchi, Susumu Uchiyama
This study evaluated how differences in the surface properties of prefillable syringe (PFS) barrels and in-solution sampling methods affect micron aggregates and protein adsorption levels. Three syringe types [glass barrel with silicone oil coating (GLS/so+), glass barrel without silicone oil coating (GLS/so-) and cyclo-olefin polymer (COP) barrel syringes] were tested with three therapeutic proteins (adalimumab, etanercept, and infliximab) using two sampling methods (aspiration or ejection). After quiescent incubation, solutions sampled by aspiration exhibited no significant change in micron aggregate concentration in any syringes, whereas those sample by ejection exhibited increased micron aggregates in both GLS syringe types...
February 5, 2018: Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/29419448/the-sex-influence-on-response-to-tumor-necrosis-factor-%C3%AE-inhibitors-and-remission-in-axial-spondyloarthritis
#14
Ennio Lubrano, Fabio Massimo Perrotta, Maria Manara, Salvatore D'Angelo, Olga Addimanda, Roberta Ramonda, Leonardo Punzi, Ignazio Olivieri, Carlo Salvarani, Antonio Marchesoni
OBJECTIVE: The aim of this study was to evaluate the influence of sex on response to treatment and disease remission in patients with axial spondyloarthritis (axSpA). METHODS: In this retrospective multicenter study, patients with axSpA, according to the Assessment of Spondyloarthritis international Society (ASAS) criteria for axSpA, and treated with adalimumab, etanercept, golimumab, or infliximab, were studied. We compared clinical characteristics, patient-reported outcomes, disease activity, function, and response to treatment in male and female patients with this disease...
February 2018: Journal of Rheumatology
https://www.readbyqxmd.com/read/29404425/gut-microbiota-offers-universal-biomarkers-across-ethnicity-in-inflammatory-bowel-disease-diagnosis-and-infliximab-response-prediction
#15
Youlian Zhou, Zhenjiang Zech Xu, Yan He, Yunsheng Yang, Le Liu, Qianyun Lin, Yuqiang Nie, Mingsong Li, Fachao Zhi, Side Liu, Amnon Amir, Antonio González, Anupriya Tripathi, Minhu Chen, Gary D Wu, Rob Knight, Hongwei Zhou, Ye Chen
Gut microbiota dysbiosis contributes to the onset and perpetuation of inflammatory bowel disease (IBD). Given that gut microbiotas vary across geography and ethnicity, it remains obscure whether any universal microbial signatures for IBD diagnosis and prognosis evaluation exist irrespective of populations. Here we profiled the fecal microbiota of a series of Chinese IBD patients and combined them with two Western IBD cohorts, PRISM and RISK, for meta-analyses. We found that the gut microbial alteration patterns in IBD are similar among Chinese and Westerners...
January 2018: MSystems
https://www.readbyqxmd.com/read/29384118/paediatric-case-series-of-drug-reaction-with-eosinophilia-and-systemic-symptoms-dress-12-year-experience-at-a-single-referral-centre-in-hong-kong-and-the-first-reported-use-of-infliximab
#16
G T Chua, J S Rosa Duque, P C Y Chong, P P W Lee, Y L Lau, M H K Ho
DRESS (drug reaction with eosinophilia and systemic symptoms) is a rare but potentially life-threatening disorder characterized by fever, skin eruption, haematological abnormalities and multi-organ dysfunction after drug exposure. The pathophysiology is thought to be related to interactions between culprit drugs, viral reactivation and T-lymphocytes activation. We report 4 paediatric patients with DRESS who were treated at our centre over the past 12 years. Most cases improved after corticosteroids. Other immunosuppressive medications were attempted in refractory cases with varied outcomes...
November 30, 2017: European Annals of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29383030/immunogenicity-of-biologics-in-inflammatory-bowel-disease
#17
Séverine Vermeire, Ann Gils, Paola Accossato, Sadiq Lula, Amy Marren
Crohn's disease and ulcerative colitis are chronic inflammatory disorders of the gastrointestinal tract. Treatment options include biologic therapies; however, a proportion of patients lose response to biologics, partly due to the formation of anti-drug antibodies (ADAbs). Concomitant immunosuppressive agents reduce the development of ADAbs. This review article aims to assess the immunogenicity of biologic therapies and their clinical implications. A comprehensive literature search was conducted for articles published January 2009 to August 2015 reporting immunogenicity to adalimumab (ADM), certolizumab pegol (CZP), golimumab, infliximab (IFX), ustekinumab, and vedolizumab in inflammatory bowel disease (IBD)...
2018: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/29379609/protocol-for-a-multicentred-randomised-controlled-trial-investigating-the-use-of-personalised-golimumab-dosing-tailored-to-inflammatory-load-in-ulcerative-colitis-the-goal-arc-study-glm-dose-optimisation-to-adequate-levels-to-achieve-response-in-colitis-led
#18
Juliette Sheridan, Carol Ann Coe, Peter Doran, Laurence Egan, Garret Cullen, David Kevans, Jan Leyden, Marie Galligan, Aoibhlinn O'Toole, Jane McCarthy, Glen Doherty
Introduction: Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD), often leading to an impaired quality of life in affected patients. Current treatment modalities include antitumour necrosis factor (anti-TNF) monoclonal antibodies (mABs) including infliximab, adalimumab and golimumab (GLM). Several recent retrospective and prospective studies have demonstrated that fixed dosing schedules of anti-TNF agents often fails to consistently achieve adequate circulating therapeutic drug levels (DL) with consequent risk of immunogenicity treatment failure and potential risk of hospitalisation and colectomy in patients with UC...
2018: BMJ Open Gastroenterology
https://www.readbyqxmd.com/read/29365183/drug-immunogenicity-in-patients-with-inflammatory-arthritis-and-secondary-failure-to-tumour-necrosis-factor-inhibitor-therapies-the-reason-study
#19
Alejandro Balsa, Raimon Sanmarti, José Rosas, Victor Martin, Ana Cabez, Susana Gómez, María Montoro
Objectives: The aims were to evaluate the prevalence of anti-drug antibodies (ADA) in patients with RA or SpA experiencing secondary failure to anti-TNF therapy and to correlate ADA presence with anti-TNF concentration and clinical response. Methods: This was a cross-sectional, observational study of patients with active RA or SpA experiencing secondary failure to etanercept (ETN), infliximab (INF) or adalimumab (ADL). Concomitant non-biologic DMARDs were permitted...
January 19, 2018: Rheumatology
https://www.readbyqxmd.com/read/29364909/intestinal-fibrosis-is-associated-with-lack-of-response-to-infliximab-therapy-in-crohn-s-disease
#20
Jessica R de Bruyn, Marte A Becker, Jessica Steenkamer, Manon E Wildenberg, Sybren L Meijer, Christianne J Buskens, Willem A Bemelman, Mark Löwenberg, Cyriel Y Ponsioen, Gijs R van den Brink, Geert R D'Haens
INTRODUCTION: Overt fibrostenotic disease is a relative contraindication for anti-TNF therapy in Crohn's disease. We hypothesized that subclinical fibrosis may also contribute to an incomplete response to anti-TNF therapy before the onset of symptomatic stenosis. METHODS: In a previous trial, patients with ileocecal Crohn's disease were randomized to either immediate ileocecal resection or medical treatment with Infliximab. In case of insufficient response to Infliximab, the latter underwent secondary ileocecal resection...
2018: PloS One
keyword
keyword
53792
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"